GELSANA THERAPEUTICS INC — Department of Defense SBIR Phase I: AFX235-CSO1
GELSANA THERAPEUTICS INC — SBIR Phase I award from Department of Defense.
- Amount
- $74,950
- Agency
- Department of Defense · Air Force
- Program / Phase
- SBIR · Phase I
- Topic
- AFX235-CSO1
- Solicitation
- X23.5
- NAICS
- —
- Place of performance
- CO
- Period
- 2023-05-01 → 2023-08-03
Description
GelSana has developed a revolutionary hydrogel technology that addresses the challenges associated with wound care. This technology offers a multitude of benefits, such as reduced inflammation at wound sites, accelerated healing time, and decreased risk o